<DOC>
	<DOCNO>NCT00002179</DOCNO>
	<brief_summary>To evaluate ability combination indinavir , zidovudine , lamivudine suppress HIV-1 infection measure : ( 1 ) maintenance HIV-1 serum viral RNA limit detection sensitive validate assay ( ultradirect assay ) ( 2 ) absence evidence infectious virus lymph node , cerebrospinal fluid ( CSF ) , peripheral mononuclear cell ( PBMCs ) , semen . It hypothesize administration indinavir , zidovudine , lamivudine result : 1 . No evidence infectious virus lymph node tissue , CSF , PBMCs , semen sample 50 % patient undetectable viral RNA sensitive validate assay available ( ultradirect assay ) least 48 week . 2 . Sustained suppression HIV-1 infection measure decrease serum viral RNA limit detection ultradirect assay least 48 week least 25 % patient . 3 . Suppression HIV-1 infection measure decrease serum viral RNA limit detection standard Amplicor assay ( i.e. , negative ) least 90 % patient Week 16 . 4 . Suppression HIV-1 infection , suggest eradication virus measure maintenance serum viral RNA limit detection ultradirect assay least 24 week discontinuation indinavir , zidovudine , lamivudine patient maintain level suppression least 120 week therapy .</brief_summary>
	<brief_title>The Effectiveness Indinavir Plus Zidovudine Plus Lamivudine HIV-Infected Patients With No Symptoms Infection</brief_title>
	<detailed_description>It hypothesize administration indinavir , zidovudine , lamivudine result : 1 . No evidence infectious virus lymph node tissue , CSF , PBMCs , semen sample 50 % patient undetectable viral RNA sensitive validate assay available ( ultradirect assay ) least 48 week . 2 . Sustained suppression HIV-1 infection measure decrease serum viral RNA limit detection ultradirect assay least 48 week least 25 % patient . 3 . Suppression HIV-1 infection measure decrease serum viral RNA limit detection standard Amplicor assay ( i.e. , negative ) least 90 % patient Week 16 . 4 . Suppression HIV-1 infection , suggest eradication virus measure maintenance serum viral RNA limit detection ultradirect assay least 24 week discontinuation indinavir , zidovudine , lamivudine patient maintain level suppression least 120 week therapy . All patient receive indinavir plus zidovudine plus lamivudine least 96 week . If evidence infectious virus , patient continue serum viral RNA level limit detection ultradirect assay least 96 week , therapy continue additional 24 week . However , additional 24 week therapy patient may continue receive triple combination drug regimen make change drug regimen treatment reduce number antiretroviral agent . After 120 week , patient continue serum viral RNA level limit detection ultradirect assay , patient discontinue antiretroviral therapy . However , evidence infectious virus , outline , patient discontinue therapy . Patients develop detectable serum viral RNA follow discontinuation therapy give option reinitiate therapy triple combination indinavir , zidovudine lamivudine . NOTE : Patients develop intolerance zidovudine may use stavudine dos per body weight direction investigator .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV1 seropositive status . CD4 count &gt; = 500 cells/mm3 . Serum viral RNA level &gt; 1000 copies/ml . Exclusion Criteria Prior Medication : Excluded : Previous antiretroviral therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Semen</keyword>
	<keyword>Monocytes</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Lymph Nodes</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>